Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys
Authors:
- Li LiangLLLi Liang
- John R. HadcockJHJohn R. Hadcock
- Philip A. IredalePIPhilip A. Iredale
- David A. GriffithDGDavid A. Griffith
- Frank S. MennitiFMFrank S. Menniti
- Stewart FactorSFStewart Factor
- J. Timothy GreenamyreJGJ. Timothy Greenamyre
- Stella M. PapaSPStella M. Papa
Open Access
- 1 October 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 323 (1) , 318-326
Abstract
Drugs acting at cannabinoid type 1 receptors (CB1) have modulatory effects on glutamate and GABA neurotransmission in basal ganglia; thus, they potentially affect motor behavior in the parkinsonian setting. Preclinical trials with diverse cannabinoid agents have shown varied results, and the precise effects of blocking cannabinoid CB1 receptors remain uncertain. We tested behavioral effects of the selective antagonist 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-[1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide benzenesulfonate (CE) as monotherapy and in combination with l-DOPA in treatment-naive and l-DOPA-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys with moderate and severe parkinsonism. Motor disability and l-DOPA-induced dyskinesias were scored with a standardized scale after subcutaneous drug administration, and plasma levels of l-DOPA were determined by high-performance liquid chromatography/electrochemical detection. CE doses ranged from 0.03 to 1 mg/kg, and l-DOPA methyl ester doses were selected as optimal and suboptimal doses (maximal and 50% of maximal responses, respectively). CE had no intrinsic effects on motor behavior regardless of the degree of parkinsonism (moderate or severe groups) or previous drug exposure (“de novo” or after l-DOPA priming). Initial CE administration did not affect development of l-DOPA antiparkinsonian responses. In coadministration trials, CE, in a dose-dependent manner, increased responses to l-DOPA (suboptimal doses). These effects were seen in both moderate and severely parkinsonian monkeys as a 30% increase of, predominantly, response duration with no effects on l-DOPA pharmacokinetics. CE did not modify levodopa-induced dyskinesias. These results suggest that selective cannabinoid CB1 antagonists may enhance the antiparkinsonian action of dopaminomimetics and possibly facilitate the use of lower doses, thereby reducing side effects.Keywords
This publication has 39 references indexed in Scilit:
- Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease modelsNature, 2007
- A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's diseaseThe FASEB Journal, 2005
- Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonismNeurobiology of Disease, 2005
- Prolongation of levodopa responses by glycineB antagonists in parkinsonian primatesAnnals of Neurology, 2004
- Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's diseaseMovement Disorders, 2002
- Postsynaptic endocannabinoid release is critical to long-term depression in the striatumNature Neuroscience, 2002
- Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosetsEuropean Journal of Neuroscience, 2001
- Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's diseaseMovement Disorders, 1998
- Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)Movement Disorders, 1995
- Dopaminergic Regulation of Cannabinoid Receptor mRNA Levels in the Rat Caudate‐Plitamen: An In Situ Hybridization StudyJournal of Neurochemistry, 1993